When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
VBLT - VBL Therapeutics nabs European patent for anti-MOSPD2 antibodies
Vascular Biogenics Ltd.
VBL Therapeutics (VBLT) has announced that the European Patent Office has granted patent (no. 3328408) covering the company's investigational anti-MOSPD2 (motile sperm domain-containing protein 2) monoclonal antibodies to treat inflammatory and autoimmune conditions. The patent expires in July 2036.VBL is currently advancing lead anti-MOSPD2 candidate VB-601 through IND-enabling studies, aiming to start a first-in-human study in H2 2021.